Stage I non-small cell lung cancer represents an early diagnosis where the tumor remains small and confined to the lung, offering patients a meaningful opportunity for treatment and long-term survival through surgery, radiation, or newer approaches being explored in clinical trials.

Understanding Your Treatment Journey with Early-Stage Lung Cancer

When someone receives a diagnosis of stage I non-small cell lung cancer, it means that abnormal cells have formed a tumor in the lung, but the cancer has not yet spread beyond that organ. This early detection is crucial because it opens up several treatment pathways aimed at removing the cancer completely and preventing it from returning. The main goal at this stage is to eliminate the tumor and give patients the best possible chance of living cancer-free for many years.

Treatment decisions for stage I non-small cell lung cancer depend heavily on several personal factors. Your overall health, how well your lungs are functioning, and your ability to recover from different types of treatment all play important roles in what your medical team recommends. Doctors also consider the exact size of your tumor and its precise location within your lung. A tumor smaller than 1 centimeter is quite different from one that is 3 or 4 centimeters, even though both might be classified as stage I.

Medical societies around the world have developed clinical guidelines—which are recommendations based on research and expert consensus—to help doctors choose the most effective treatments for each patient’s situation. At the same time, researchers continue to explore new therapies through clinical trials, testing whether innovative drugs or treatment combinations might work even better than current standard approaches. This means that patients today have access not only to proven treatments but also to cutting-edge options that could improve their outcomes.

Standard Surgical Approaches for Early Lung Cancer

Surgery is the cornerstone of treatment for most people with stage I non-small cell lung cancer, provided they are healthy enough to undergo the procedure. The operation aims to remove the tumor along with a margin of healthy tissue around it, ensuring that no cancer cells are left behind. When doctors say someone is “well enough” for surgery, they are evaluating whether the person’s heart, lungs, and overall physical condition can handle the stress of the operation and the recovery period that follows.^[10]

The most common type of surgery is called a lobectomy, which means removing the entire lobe of the lung where the tumor is located. Since the human lung is divided into lobes—three on the right side and two on the left—taking out one lobe leaves the remaining lobes to continue functioning. Studies have shown that lobectomy offers the best chance of completely removing the cancer and preventing it from coming back. During this surgery, the surgeon also removes and examines lymph nodes from the chest to confirm that cancer has not spread beyond the lung.^[10]

For patients who have weaker lung function or other health concerns that make a lobectomy risky, surgeons may perform a smaller operation called a wedge resection or segmental resection. These procedures remove only the tumor and a surrounding margin of healthy tissue, preserving more of the lung. While this approach is gentler on the body, it may carry a slightly higher risk that small amounts of cancer could remain, which is why it is typically reserved for patients who cannot safely undergo a full lobectomy.^[10]

Another specialized surgical option is a sleeve resection, used when the tumor is located in one of the airway tubes (bronchi) leading into the lung. Instead of removing an entire lobe, the surgeon cuts out the section of the airway containing the tumor and reconnects the healthy portions. This technique can preserve more lung tissue while still achieving complete cancer removal.^[10]

Whenever possible, surgeons use minimally invasive techniques, which involve making smaller incisions and using specialized instruments. This approach, sometimes called video-assisted thoracic surgery, typically results in less pain, shorter hospital stays, and faster recovery compared to traditional open surgery. However, not every patient or tumor is suitable for minimally invasive methods, and the surgeon will choose the safest approach based on individual circumstances.^[12]

After surgery, the tissue that was removed is sent to a laboratory for detailed examination. If the pathologist finds cancer cells at the edges of the removed tissue—a situation called positive margins—it means some cancer may have been left behind. In such cases, patients might need a second surgery to remove more tissue, or they may receive additional treatment such as radiation therapy.^[10]

Radiation Therapy When Surgery Is Not an Option

Not everyone with stage I lung cancer can have surgery. Some people have other serious health conditions affecting their heart or lungs that make surgery too dangerous. Others may simply choose not to undergo an operation. For these patients, radiation therapy offers a powerful alternative that can still aim to eliminate the cancer.^[10]

The most advanced form of radiation for early lung cancer is called stereotactic body radiotherapy, often shortened to SBRT. This technique delivers very high doses of radiation with extreme precision, targeting the tumor while minimizing exposure to surrounding healthy tissue. Unlike traditional radiation that requires many weeks of daily treatments, SBRT typically involves only a few sessions—sometimes as few as three to five treatments over one to two weeks. The radiation beams come from multiple angles, all converging on the tumor like spokes of a wheel meeting at the center.^[10]

SBRT has become an important option for patients who cannot have surgery, with studies showing that it can be highly effective for treating small lung tumors. The procedure itself is painless and does not require any incisions or recovery time like surgery would. Patients lie still on a treatment table while the machine moves around them, and each session typically lasts less than an hour, though the actual radiation delivery takes only minutes.^[12]

If SBRT is not available or not suitable for a particular patient, doctors may recommend hypofractionated radiation therapy. This approach uses slightly lower doses per treatment but still fewer sessions than traditional radiation. Another option is 3D conformal radiation therapy or intensity-modulated radiation therapy (IMRT), which are more conventional forms that deliver radiation over several weeks but with careful planning to protect healthy tissues.^[10]

Side effects from radiation therapy depend on the dose, the area being treated, and individual factors. Common effects include fatigue, skin changes in the treatment area similar to mild sunburn, and sometimes inflammation of the lung tissue called pneumonitis, which can cause coughing or shortness of breath. Most side effects improve after treatment ends, though some people experience long-term changes. Your radiation oncology team will monitor you carefully and provide medications or other support to manage any symptoms that arise.

The Role of Chemotherapy After Surgery

Chemotherapy uses drugs that travel throughout the body to kill cancer cells. For stage I non-small cell lung cancer, chemotherapy is not always necessary after surgery, but it may be recommended in certain situations. The decision depends on the substage of your cancer and your overall health.^[10]

For stage IB disease—where the tumor is between 3 and 4 centimeters—doctors may offer chemotherapy after surgery if you are healthy enough to tolerate it. This type of treatment, given after surgery to kill any remaining cancer cells that cannot be seen, is called adjuvant chemotherapy. Research has shown that it might help some people with early-stage lung cancer live longer by reducing the risk that cancer will return.^[10]

The most commonly used chemotherapy combination for this situation includes two drugs: cisplatin and vinorelbine. Cisplatin is a platinum-based drug that damages the DNA of cancer cells, preventing them from dividing and growing. Vinorelbine interferes with cancer cells’ ability to divide by affecting their internal structure. Together, these drugs work through different mechanisms to kill any lingering cancer cells.^[10]

Some patients cannot receive cisplatin because it can affect kidney function or cause other side effects they cannot tolerate. In these cases, doctors may substitute carboplatin, another platinum-based drug that tends to be gentler on the kidneys, combined with paclitaxel, which also disrupts cancer cell division. Your medical team will discuss which combination is best for your individual situation.^[10]

Chemotherapy is typically given in cycles, with treatment periods followed by rest periods to allow your body to recover. A typical course might involve four to six cycles, with each cycle lasting three to four weeks. Side effects vary depending on which drugs are used but can include nausea, fatigue, increased risk of infection due to lower white blood cell counts, hair loss, and numbness or tingling in the hands and feet (called peripheral neuropathy). Your healthcare team will provide medications and support to help manage these side effects and will adjust your treatment plan if needed.

Immunotherapy: A Newer Standard Approach

Immunotherapy represents a significant advance in cancer treatment, working by helping your own immune system recognize and attack cancer cells. For stage I non-small cell lung cancer, one specific immunotherapy drug has become part of standard care in certain situations.^[10]

Atezolizumab, sold under the brand name Tecentriq, is a type of drug called a PD-L1 checkpoint inhibitor. Cancer cells sometimes produce a protein called PD-L1 that acts like a disguise, telling the immune system to leave them alone. Atezolizumab blocks this protein, essentially removing the cancer’s disguise and allowing immune cells to recognize and destroy cancer cells. This drug may be offered by itself after you have had surgery to completely remove your stage I tumor and have completed chemotherapy without your cancer growing or spreading.^[10]

The goal of using atezolizumab in this setting is to help prevent the cancer from coming back. By stimulating the immune system to remain vigilant against any remaining cancer cells, the treatment aims to provide longer-lasting protection than chemotherapy alone might offer. However, not every patient will need or benefit from this treatment, and your doctor will discuss whether it is appropriate for your specific situation.

Immunotherapy side effects are different from chemotherapy side effects because they involve activating the immune system rather than directly killing cells. The immune system might become overactive and attack normal tissues, causing inflammation. This can affect various organs, leading to symptoms like fatigue, diarrhea, skin rash, or hormone imbalances affecting the thyroid or other glands. Most side effects are manageable with medication, but they require careful monitoring by your healthcare team.

Innovative Treatments Being Tested in Clinical Trials

While surgery, radiation, chemotherapy, and immunotherapy represent proven treatments for stage I non-small cell lung cancer, researchers continue to explore new approaches through clinical trials. These studies test whether experimental drugs or new combinations of existing treatments might improve outcomes even further.

One area of active investigation involves using immunotherapy before surgery, known as neoadjuvant treatment. Early studies have suggested that giving immunotherapy drugs before removing the tumor might help shrink it, making surgery easier, and might also stimulate a stronger immune response against any cancer cells that remain after surgery. Some trials are testing combinations of immunotherapy with chemotherapy given before surgery for stage I and II non-small cell lung cancer.^[12]

Researchers are also studying targeted therapy drugs that attack specific genetic changes found in some lung cancer cells. These drugs work differently from chemotherapy, focusing on particular molecular pathways that cancer cells use to grow and survive. For example, if testing reveals that your tumor has certain genetic mutations—such as changes in genes called EGFR, ALK, or ROS1—you might be eligible for clinical trials testing targeted drugs designed to block those specific abnormalities. These drugs typically cause different side effects than chemotherapy, often affecting the skin, digestive system, or blood pressure.

Some clinical trials are exploring whether combining different types of treatment—such as immunotherapy with targeted drugs, or new radiation techniques with novel drugs—might work better than any single approach. Others are investigating whether certain patients with very small tumors might be able to avoid surgery altogether by using advanced radiation or other non-invasive methods.

Clinical trials typically progress through phases. Phase I trials focus primarily on safety, determining what dose of a new drug can be given safely and what side effects occur. Phase II trials begin to evaluate whether the treatment actually works against cancer, measuring whether tumors shrink or stop growing. Phase III trials compare the new treatment directly against standard treatment to see if it is more effective. Each phase enrolls more patients than the previous one, gradually building evidence about whether a new treatment should become standard care.

Patients interested in clinical trials can discuss options with their medical team. Trials may be available at major cancer centers in various countries, including the United States, Canada, and European nations. Eligibility requirements vary depending on the specific trial, but generally include factors like the exact stage and type of your cancer, your overall health, and whether you have received previous treatments. Participating in a clinical trial provides access to new treatments before they are widely available and contributes to advancing medical knowledge that will help future patients.

Most common treatment methods

• Surgery
  • Lobectomy—removing the lobe of the lung containing the tumor, offering the best chance of complete cancer removal
  • Wedge or segmental resection—removing the tumor with surrounding healthy tissue for patients with reduced lung function
  • Sleeve resection—removing tumor from airway tubes while preserving lung tissue
  • Minimally invasive techniques using smaller incisions and specialized instruments for faster recovery
• Radiation therapy
  • Stereotactic body radiotherapy (SBRT)—delivering high-dose radiation in just a few treatment sessions with extreme precision
  • Hypofractionated radiation—using fewer sessions than traditional radiation with moderate doses
  • 3D conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) for patients who cannot tolerate higher doses
• Chemotherapy
  • Cisplatin combined with vinorelbine—the most common drug combination given after surgery for stage IB disease
  • Carboplatin combined with paclitaxel—alternative for patients who cannot tolerate cisplatin
  • Given in cycles over several months to eliminate any remaining cancer cells after surgery
• Immunotherapy
  • Atezolizumab (Tecentriq)—a PD-L1 checkpoint inhibitor that helps the immune system attack cancer cells
  • Given after surgery and chemotherapy to reduce the risk of cancer returning
  • Works by blocking proteins that prevent immune cells from recognizing cancer